Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS

Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS

The recent first global approval of ocrelixumab has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Continue reading “Ocrelizumab (Ocrevus™): First Global Approval – making a B-line to crushing the most aggressive form of MS”